Techsomed Announces Field Evaluation of its Image Guided Ablation Therapy Software Using GE HealthCare LOGIQ™ Ultrasound Systems at Top US Clinical Sites

Techsomed Ltd., the developer of BioTrace, an AI powered software platform for real time ablation zone imaging and treatment precision enhancement, announced today a field evaluation of its BioTraceIO360 software with GE HealthCare LOGIQ™ E10 Series ultrasound imaging technology. The evaluation is intended to introduce an automated visualization and control solution for liver ablation procedures.

Thermal ablation is a minimally invasive therapy to treat liver tumors. However, its true potential is hindered due to limited visualization throughout the procedure, leading to a major gap between planned treatment and actual outcomes. This gap may subsequently cause unnecessary risks to patients, either in the damage of healthy tissue or incomplete tumor cell destruction, associated with local tumor recurrence rates.

Techsomed’s BioTrace platform, currently in advanced clinical evaluation, is a significant advancement in Image Guided Ablation Therapy. The technology leverages standard imaging—such as ultrasound (US) along with computed tomography (CT) or magnetic resonance imaging (MRI).

The BioTrace platform is designed to provide visualization of the full extent of the ablation zone in real-time together with smart, personalized treatment planning and assessment tools, allowing physicians to provide their patients with optimized care.

“By combining the outstanding image quality of the LOGIQ™ E10 with our BioTrace generative AI capabilities for personalized treatment and real time ablation zone visualization, we aim to offer a new level of treatment optimization and precision for the benefit of both patients and physicians.  We are very excited for this opportunity as this initiative marks a significant milestone in our commitment to advancing patient care and driving scientific progress in the ablation market worldwide.” said Yossi Abu, CEO of TechsoMed.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version